Stay updated on Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.

Latest updates to the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange Detected- The record history shows a new revision v3.4.2 added and v3.4.1 removed, indicating a minor update to the page’s revision history. There are no visible changes to study data or page content.SummaryDifference0.1%

- Check17 days agoChange DetectedThe page history now shows an addition of Revision: v3.4.1 and removal of Revision: v3.4.0, reflecting a minor update to the record’s version history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check24 days agoChange DetectedUI updates add a Show glossary option, green and red highlights to indicate additions and deletions, and a Revision: v3.4.0, with No FEAR Act data removal noted (v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check39 days agoChange DetectedRevision: v3.3.4 was added to the record history. Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check60 days agoChange DetectedThe history now includes Revision: v3.3.3, and the HHS Vulnerability Disclosure and Revision: v3.3.2 entries were removed.SummaryDifference0.2%

- Check74 days agoChange DetectedThe record history now includes core results-related sections such as Results Posted, Outcome Measures (Results), Adverse Events, Baseline Characteristics, and Participant Flow, along with More Information and Limitations and Caveats; the previous entry 'Results Submitted' appears to be removed.SummaryDifference1%

Stay in the know with updates to Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.